
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. demonstrates a promising growth trajectory with Cabometyx, which has established itself as the leading TKI in the renal cell carcinoma (RCC) market, capturing 46% of total prescriptions and achieving a significant 15% year-over-year growth in volume. The company is further enhancing its market position by expanding its gastrointestinal sales team to capitalize on the increasing demand for Cabometyx, particularly in second-line neuroendocrine tumors (NET) and in preparation for the launch of zanzalintinib in colorectal cancer (CRC). Financial forecasts for Cabometyx sales have been positively revised, reflecting increased expectations with projected revenue reaching $2.8 billion by FY28, bolstered by the positive outcomes of pivotal clinical trials and a strong balance sheet that supports sustained profitability.
Bears say
Exelixis Inc. reported a gross-to-net (GTN) reduction from 30.2% in 3Q25 to 28.5% in 4Q25, primarily due to decreased PHS/340B volume, indicating declining pricing power. The company's 4Q25 sales for Cabometyx fell short of both internal and consensus estimates, reflecting a stagnant performance compared to the previous quarter and highlighting growing competitive pressures in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) markets. Additionally, ongoing risks, including commercial challenges with Cabometyx, the potential for unfavorable clinical outcomes for zanzalintinib, and the threat of generic erosion, underscore uncertainties surrounding Exelixis's future revenue streams.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares